Insider Buying: Synergy Pharmaceuticals CEO Purchases 4,000 Shares of Stock (SGYP)
Synergy Pharmaceuticals (NASDAQ:SGYP) CEO Gary S. Jacob purchased 4,000 shares of Synergy Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average cost of $4.18 per share, for a total transaction of $16,720.00. Following the transaction, the chief executive officer now directly owns 338,034 shares of the company’s stock, valued at approximately $1,412,982. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 4.42 on Friday. Synergy Pharmaceuticals has a 1-year low of $3.39 and a 1-year high of $6.70. The stock’s 50-day moving average is $4.20 and its 200-day moving average is $4.9. The company’s market cap is $414.1 million.
Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.05. On average, analysts predict that Synergy Pharmaceuticals will post $-0.86 earnings per share for the current fiscal year.
Separately, analysts at Aegis raised their price target on shares of Synergy Pharmaceuticals to $28.00 in a research note on Monday, March 24th. Four analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $16.33.
Synergy Pharmaceuticals, Inc is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:SGYP), disorders and diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.